Brieflist

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Forecast: not open for applications yet. Dates are the funder's estimate. Save a search and Brieflist marks it when it opens (Grants Pro e-mails you), or get the free weekly digest:

This is a forecast: the funder has announced the grant but applications are not open yet. Dates may change.

The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant …

Read the official page on Grants.gov ↗ Get new grants like this

Funder
Food and Drug Administration (Department of Health and Human Services)
Where
🇺🇸 United States
Status
Forecast
Funding
$250k–$500k per award
Expected awards
2
Who can apply
Most organisations
Topics
Agriculture & food Justice & security
Opportunity number
FOR-FD-24-005
Instrument
Cooperative agreement

About this grant

The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products.

Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"; Independent school districts; Public and State controlled institutions of higher education; Private institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); State governments; Small businesses; County governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Special district governments. Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →

More from this funder: 12 open opportunities from Food and Drug Administration (FDA).

Applying? Read how to write a winning grant proposal.

Data from Grants.gov, US federal government (public domain). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.

Similar grants